Studii clinice

La ora actuala exista numeroase studii clinice care probeaza eficienta  Inozitolului si a fosfatilor acestuia (IP3, IP6). Aceste studii s-au desfasurat in intreaga lume de la mijlocul anilor ’80 si pana in prezent, demonstrand ca aceste substante active au un spectru larg de actiune: plamani, aparat cardiovascular, ficat, rinichi, intestin, sange, piele, sistemul osos, prostata, col uterin, tesuturi moi, san. Vom enumera mai jos cateva din aceste studii1-14. In urma studiilor clinice  s-au constatat urmatoarele efecte: 

• efectul antioxidant si citotoxic asupra celulelor anormale de la nivelul ovarelor, sanilor, ficatului, sangelui;
• actiune antiplachetara;
• actiune adjuvanta de reducere a colesterilului si a trigliceridelor;
• relatia invers proportionala intre nivelul de Inozitol si a fosfolipidelor acestuia in organism si nivelul glicemiei;
• actiune de reducere a calcifierilor de la nivelul rinichilor;
• efectul de crestere a densitatii minerale osoase prin suplimentarea dietei cu IP6;
• reducerea riscului de pierdere a densitatii osoase si a riscului de fractura la femei aflate la menopauza prin adaugarea in dieta a IP6;
• reducerea actiunii de formare a tesutului fibros la nivelul plamanilor;
• imbunatatirea actiunii citotoxice a metodei clasice cu citostatice prin suplimentarea dietei cu Inozitol si IP6,  imbunatatirea calitatii vietii.

1. Protection against cancer by dietary IP6 and inositol.

Publicat in Nutrition and Cancer  2006;55(2):109-25.

Vucenik I, Shamsuddin AM.

Department of Pathology, University of Maryland School of Medicine, MD 21201, USA.

(Protectia impotriva cancerului prin suplimentul nutritional IP6 si inozitol)

http://www.ncbi.nlm.nih.gov/pubmed/?term=Protection+against+cancer+by+dietary+IP6+and+inositol

2. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic.

Publicat in The Journal of Nutrition 2003 Nov;133(11 Suppl 1):3778S-3784S

Vucenik I, Shamsuddin AM.

Department of Medical and Research Technology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

(Inhibitia cancerului prin inozitol hexafosfat (IP6) si inozitol: de la laborator la clinica)

http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer+inhibition+by+inositol+hexaphosphate+(IP6)+and+inositol%3A+from+laboratory+to+clinic  

3. Effects of exogenous inositol hexakisphosphate (InsP(6)) on the levels of InsP(6) and of inositol trisphosphate (InsP(3)) in malignant cells, tissues and biological fluids.

Publicat in Life Sciences 2002 Aug 16;71(13):1535-46.

Grases F, Simonet BM, Vucenik I, Perelló J, Prieto RM, Shamsuddin AM.

Laboratory of Renal Lithiasis Research, Faculty of Science, University of Balearic Islands, Ctra. Valldemossa Km 7.5, 07071 Palma de Mallorca, Spain.

(Efectele inozitolului hexakisfosfat (InsP(6), acid fitic) exogen si a inozitolului trifosfat (InsP(3)) in celulele neoplazice, tesuturi si fluide biologice)

http://www.ncbi.nlm.nih.gov/pubmed/?term=Effects+of+exogenous+inositol+hexakisphosphate+(InsP(6))+on+the+levels+of+InsP(6)+and+of+inositol+trisphosphate+(InsP(3))+in+malignant+cells%2C+tissues+and+biological+fluids  

4. Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction.

Publicat in Blood 2011 Mar 10;117(10):2924-34. doi: 10.1182/blood-2010-09-307405. Epub 2010 Dec 30.

Zhong F, Harr MW, Bultynck G, Monaco G, Parys JB, De Smedt H, Rong YP, Molitoris JK, Lam M, Ryder C, Matsuyama S, Distelhorst CW.

Department of Medicine and Pharmacology, Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center, and University Hospitals Case Medical Center, Cleveland, OH, USA.

(Inducerea apoptozei  Ca²+ mediata, in celulele leucemice din leucemia limfocitara cronica, prin intreruperea mediata de peptide a interactiunii receptorului - proteina Bcl2-IP3)

http://www.ncbi.nlm.nih.gov/pubmed/?term=Induction+of+Ca%C2%B2%2B-driven+apoptosis+in+chronic+lymphocytic+leukemia+cells+by+peptide-mediated+disruption+of+Bcl-2-IP3+receptor+interaction  

5. Antioxidant and cytotoxicity effect of rice bran phytic acid as an anticancer agent on ovarian, breast and liver cancer cell lines.

Publicat in Malaysian Journal of Nutrition 2011 Dec;17(3):367-75.

Norhaizan ME, Ng SK, Norashareena MS, Abdah MA.

Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

(Efectul antioxidant si citotoxicitatea acidului fitic din tarate de orez, ca agent antineoplazic pe linii celulare de cancer ovarian, cancer mamar si cancer hepatic)

http://www.ncbi.nlm.nih.gov/pubmed/?term=Induction+of+Ca%C2%B2%2B-driven+apoptosis+in+chronic+lymphocytic+leukemia+cells+by+peptide-mediated+disruption+of+Bcl-2-IP3+receptor+interaction  

6. IP6 in treatment of liver cancer. II. Intra-tumoral injection of IP6 regresses pre-existing human liver cancer xenotransplanted in nude mice.

Publicat in Anticancer Research 1998 Nov-Dec;18(6A):4091-6.

Vucenik I, Zhang ZS, Shamsuddin AM.

Department of Medical and Research Technology, University of Maryland School of Medicine, Baltimore 21201, USA.

(IP6 in tratamentul cancerului hepatic. II. Administrarea intratumorala de IP6 produce regresia cancerului uman hepatic, preexistent, xenotransplantat la soareci fara blana)

http://www.ncbi.nlm.nih.gov/pubmed/?term=IP6+in+treatment+of+liver+cancer.+II.+Intra-tumoral+injection+of+IP6+regresses+pre-existing+human+liver+cancer+xenotransplanted+in+nude+mice  

7. Antiplatelet activity of inositol hexaphosphate (IP6).

Publicat in Anticancer Research 1999 Sep-Oct;19(5A):3689-93.

Vucenik I, Podczasy JJ, Shamsuddin AM.

Department of Medical and Research Technology, University of Maryland School of Medicine Baltimore 21201, USA.

(Activitatea antiplachetara a inozitolului hexafosfat (IP6))

http://www.ncbi.nlm.nih.gov/pubmed/?term=Antiplatelet+activity+of+inositol+hexaphosphate+(IP6)  

8. IP6: a novel anti-cancer agent.

Publicat in Life Sciences 1997;61(4):343-54.

Shamsuddin AM, Vucenik I, Cole KE.

University of Maryland School of Medicine, Baltimore 21201-1192, U.S.A.

(IP6: un nou agent anti cancer)

http://www.ncbi.nlm.nih.gov/pubmed/9244360  

9. Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women.

Publicat in European Journal of Nutrition 2013 Mar;52(2):717-26. doi: 10.1007/s00394-012-0377-6. Epub 2012 May 22.

López-González AA, Grases F, Monroy N, Marí B, Vicente-Herrero MT, Tur F, Perelló J.

Servicio de Prevención de Riesgos Laborales de GESMA (Gestión Sanitaria de Mallorca), Palma de Mallorca, Spain.

(Efectul de protectie a mio-inozitol hexafosfat (fitat) asupra pierderii de masa osoasa, la femei in post-menopauza)

http://www.ncbi.nlm.nih.gov/pubmed/?term=Protective+effect+of+myo-inositol+hexaphosphate+(phytate)+on+bone+mass+loss+in+postmenopausal+women  

10. Phytate (myo-inositol hexaphosphate) and risk factors for osteoporosis.

Publicat in Jornal of Medicinal Food  2008 Dec;11(4):747-52. doi: 10.1089/jmf.2008.0087.

López-González AA, Grases F, Roca P, Mari B, Vicente-Herrero MT, Costa-Bauzá A.

Servicio de Prevención de Riesgos Laborales, Gestión Sanitaria de Mallorca, Palma de Mallorca, Spain.

(Fitat (mio-inozitol hexafosfat) si factorii de risc pentru osteoporoza)

http://www.ncbi.nlm.nih.gov/pubmed/?term=Phytate+(myo-inositol+hexaphosphate)+and+risk+factors+for+osteoporosis  

11. Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment.

Publicat in Anticancer Research 1999 Sep-Oct;19(5A):3717-22.

Grases F, Costa-Bauzá A.

Laboratory of Investigation into Renal Lithiasis, Faculty of Sciences, University of Illes Balears, Palma de Mallorca, Spain.

(Fitat (IP6) este un agent puternic pentru prevenirea calcificarilor in fluidele biologice: utilitatea in tratamentul litiazei renale)

http://www.ncbi.nlm.nih.gov/pubmed/?term=Phytate+(IP6)+is+a+powerful+agent+for+preventing+calcifications+in+biological+fluids%3A+usefulness+in+renal+lithiasis+treatment  

12. Phytic acid, an iron chelator, attenuates pulmonary inflammation and fibrosis in rats after intratracheal instillation of asbestos.

Publicat in Toxicologic Pathology 1995 Nov-Dec;23(6):689-95.

Kamp DW, Israbian VA, Yeldandi AV, Panos RJ, Graceffa P, Weitzman SA.

Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA.

(Acidul fitic, un chelator de fier, atenueaza inflamatia pulmonara si fibroza, la sobolani, dupa instilare intratraheala a azbestului)

http://www.ncbi.nlm.nih.gov/pubmed/?term=Phytic+acid%2C+an+iron+chelator%2C+attenuates+pulmonary+inflammation+and+fibrosis+in+rats+after+intratracheal+instillation+of+asbestos  

13. Inositol hexaphosphate (IP6) as an anti-neoplastic and lipid-lowering agent.

Publicat in Anticancer Research 1999 Sep-Oct;19(5A):3699-702.

Jariwalla RJ.

California Institute for Medical Research, Santa Clara Valley Medical Center, San Jose 95128, USA.

(Inozitol hexafosfat (IP6), un agent anti neoplazic si un agent hipolipemiant)

http://www.ncbi.nlm.nih.gov/pubmed/?term=Inositol+hexaphosphate+(IP6)+as+an+anti-neoplastic+and+lipid-lowering+agent  

14. Metabolism and function of myo-inositol and inositol phospholipids.

Publicat in Annual  Review of Nutrition 1986;6:563-97.

Holub BJ

(Metabolismul si functiile mio-inozitolului si a inozitol-fosfolipidelor)

http://www.ncbi.nlm.nih.gov/pubmed/2425833